A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

NCT06832618 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Ruxolitinib
DRUG: Vehicle Cream

Sponsor

Incyte Corporation